nodes	percent_of_prediction	percent_of_DWPC	metapath
Pranlukast—NFKB1—psoriasis	0.502	0.765	CbGaD
Pranlukast—TNF—psoriasis	0.154	0.235	CbGaD
Pranlukast—ABCC2—Mycophenolate mofetil—psoriasis	0.0373	0.174	CbGbCtD
Pranlukast—ABCC2—Cyclosporine—psoriasis	0.0283	0.132	CbGbCtD
Pranlukast—ABCC2—Dexamethasone—psoriasis	0.0186	0.0868	CbGbCtD
Pranlukast—CYP3A4—Calcitriol—psoriasis	0.0163	0.076	CbGbCtD
Pranlukast—ABCC2—Methotrexate—psoriasis	0.015	0.0697	CbGbCtD
Pranlukast—CYP2C9—Cholecalciferol—psoriasis	0.0145	0.0673	CbGbCtD
Pranlukast—CYP3A4—Methoxsalen—psoriasis	0.0127	0.0591	CbGbCtD
Pranlukast—CYP2C9—Cyclosporine—psoriasis	0.00951	0.0443	CbGbCtD
Pranlukast—CYP3A4—Cholecalciferol—psoriasis	0.00841	0.0392	CbGbCtD
Pranlukast—CYP3A4—Triamcinolone—psoriasis	0.00729	0.034	CbGbCtD
Pranlukast—CYP3A4—Mycophenolate mofetil—psoriasis	0.00729	0.034	CbGbCtD
Pranlukast—CYP2C9—Dexamethasone—psoriasis	0.00626	0.0291	CbGbCtD
Pranlukast—CYP3A4—Betamethasone—psoriasis	0.00626	0.0291	CbGbCtD
Pranlukast—CYP3A4—Prednisolone—psoriasis	0.00618	0.0287	CbGbCtD
Pranlukast—CYP3A4—Hydrocortisone—psoriasis	0.00585	0.0272	CbGbCtD
Pranlukast—CYP3A4—Prednisone—psoriasis	0.00583	0.0271	CbGbCtD
Pranlukast—CYP3A4—Cyclosporine—psoriasis	0.00553	0.0257	CbGbCtD
Pranlukast—CYP3A4—Dexamethasone—psoriasis	0.00364	0.0169	CbGbCtD
Pranlukast—NFKB1—Immune System—ERAP1—psoriasis	5.06e-05	0.000392	CbGpPWpGaD
Pranlukast—TNF—Vitamin B12 Metabolism—IL6—psoriasis	5.06e-05	0.000391	CbGpPWpGaD
Pranlukast—TNF—TNF alpha Signaling Pathway—NFKB1—psoriasis	5.03e-05	0.000389	CbGpPWpGaD
Pranlukast—NFKB1—Fc epsilon receptor (FCERI) signaling—TYK2—psoriasis	5.02e-05	0.000388	CbGpPWpGaD
Pranlukast—NFKB1—Innate Immune System—HLA-C—psoriasis	4.99e-05	0.000386	CbGpPWpGaD
Pranlukast—NFKB1—Glucocorticoid receptor regulatory network—TP53—psoriasis	4.96e-05	0.000384	CbGpPWpGaD
Pranlukast—IL5—Immune System—SOCS1—psoriasis	4.96e-05	0.000384	CbGpPWpGaD
Pranlukast—TNF—Spinal Cord Injury—IFNG—psoriasis	4.95e-05	0.000383	CbGpPWpGaD
Pranlukast—NFKB1—Innate Immune System—TNFAIP3—psoriasis	4.93e-05	0.000382	CbGpPWpGaD
Pranlukast—NFKB1—Regulation of toll-like receptor signaling pathway—JUN—psoriasis	4.93e-05	0.000381	CbGpPWpGaD
Pranlukast—CYSLTR1—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	4.89e-05	0.000378	CbGpPWpGaD
Pranlukast—NFKB1—Cytokine Signaling in Immune system—HLA-A—psoriasis	4.88e-05	0.000377	CbGpPWpGaD
Pranlukast—NFKB1—TRAF6 Mediated Induction of proinflammatory cytokines—IL6—psoriasis	4.88e-05	0.000377	CbGpPWpGaD
Pranlukast—NFKB1—Toll-Like Receptors Cascades—JUN—psoriasis	4.87e-05	0.000377	CbGpPWpGaD
Pranlukast—NFKB1—Apoptosis—TP53—psoriasis	4.87e-05	0.000377	CbGpPWpGaD
Pranlukast—TNF—MicroRNAs in cardiomyocyte hypertrophy—STAT3—psoriasis	4.86e-05	0.000376	CbGpPWpGaD
Pranlukast—NFKB1—SIDS Susceptibility Pathways—CXCL8—psoriasis	4.83e-05	0.000374	CbGpPWpGaD
Pranlukast—TNF—Toll-like Receptor Signaling Pathway—JUN—psoriasis	4.81e-05	0.000372	CbGpPWpGaD
Pranlukast—NFKB1—Adaptive Immune System—HLA-C—psoriasis	4.79e-05	0.000371	CbGpPWpGaD
Pranlukast—NFKB1—BDNF signaling pathway—JUN—psoriasis	4.79e-05	0.000371	CbGpPWpGaD
Pranlukast—NFKB1—Toll-like Receptor Signaling Pathway—TNF—psoriasis	4.73e-05	0.000366	CbGpPWpGaD
Pranlukast—TNF—Toll-like Receptor Signaling Pathway—NFKB1—psoriasis	4.63e-05	0.000358	CbGpPWpGaD
Pranlukast—NFKB1—Integrated Breast Cancer Pathway—JUN—psoriasis	4.61e-05	0.000357	CbGpPWpGaD
Pranlukast—TNF—Developmental Biology—CARM1—psoriasis	4.61e-05	0.000357	CbGpPWpGaD
Pranlukast—TNF—Spinal Cord Injury—CXCL8—psoriasis	4.6e-05	0.000356	CbGpPWpGaD
Pranlukast—NFKB1—Apoptosis Modulation and Signaling—TP53—psoriasis	4.56e-05	0.000353	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—HCAR2—psoriasis	4.56e-05	0.000353	CbGpPWpGaD
Pranlukast—NFKB1—Glucocorticoid receptor regulatory network—IL6—psoriasis	4.54e-05	0.000351	CbGpPWpGaD
Pranlukast—NFKB1—Myometrial Relaxation and Contraction Pathways—JUN—psoriasis	4.52e-05	0.000349	CbGpPWpGaD
Pranlukast—TNF—Folate Metabolism—TP53—psoriasis	4.5e-05	0.000348	CbGpPWpGaD
Pranlukast—NFKB1—SIDS Susceptibility Pathways—JUN—psoriasis	4.49e-05	0.000348	CbGpPWpGaD
Pranlukast—NFKB1—Immune System—DDX58—psoriasis	4.46e-05	0.000345	CbGpPWpGaD
Pranlukast—NFKB1—Cytokine Signaling in Immune system—HLA-DRB1—psoriasis	4.46e-05	0.000345	CbGpPWpGaD
Pranlukast—NFKB1—MyD88 cascade initiated on plasma membrane—IL6—psoriasis	4.41e-05	0.000341	CbGpPWpGaD
Pranlukast—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	4.41e-05	0.000341	CbGpPWpGaD
Pranlukast—IL5—Immune System—CD8A—psoriasis	4.4e-05	0.00034	CbGpPWpGaD
Pranlukast—TNF—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	4.39e-05	0.00034	CbGpPWpGaD
Pranlukast—NFKB1—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—IL6—psoriasis	4.37e-05	0.000338	CbGpPWpGaD
Pranlukast—NFKB1—Selenium Micronutrient Network—IL6—psoriasis	4.29e-05	0.000332	CbGpPWpGaD
Pranlukast—NFKB1—MyD88 dependent cascade initiated on endosome—IL6—psoriasis	4.29e-05	0.000332	CbGpPWpGaD
Pranlukast—NFKB1—Cytokine Signaling in Immune system—ICAM1—psoriasis	4.28e-05	0.000331	CbGpPWpGaD
Pranlukast—NFKB1—MAPK Signaling Pathway—JUN—psoriasis	4.23e-05	0.000328	CbGpPWpGaD
Pranlukast—IL5—Immune System—HLA-B—psoriasis	4.23e-05	0.000327	CbGpPWpGaD
Pranlukast—NFKB1—TCR Signaling Pathway—IL6—psoriasis	4.22e-05	0.000326	CbGpPWpGaD
Pranlukast—NFKB1—Cellular Senescence—CXCL8—psoriasis	4.2e-05	0.000325	CbGpPWpGaD
Pranlukast—IL5—Cytokine Signaling in Immune system—IL6—psoriasis	4.18e-05	0.000324	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—CCL20—psoriasis	4.18e-05	0.000323	CbGpPWpGaD
Pranlukast—NFKB1—Signaling by NGF—NFKBIA—psoriasis	4.17e-05	0.000323	CbGpPWpGaD
Pranlukast—NFKB1—Innate Immune System—HLA-E—psoriasis	4.14e-05	0.000321	CbGpPWpGaD
Pranlukast—NFKB1—BDNF signaling pathway—STAT3—psoriasis	4.14e-05	0.000321	CbGpPWpGaD
Pranlukast—NFKB1—Toll Like Receptor 9 (TLR9) Cascade—IL6—psoriasis	4.14e-05	0.00032	CbGpPWpGaD
Pranlukast—NFKB1—TNF alpha Signaling Pathway—IL6—psoriasis	4.14e-05	0.00032	CbGpPWpGaD
Pranlukast—TNF—Folate Metabolism—IL6—psoriasis	4.12e-05	0.000318	CbGpPWpGaD
Pranlukast—NFKB1—MyD88:Mal cascade initiated on plasma membrane—IL6—psoriasis	4.07e-05	0.000315	CbGpPWpGaD
Pranlukast—NFKB1—Fc epsilon receptor (FCERI) signaling—JUN—psoriasis	4.06e-05	0.000314	CbGpPWpGaD
Pranlukast—TNF—Regulation of toll-like receptor signaling pathway—CXCL8—psoriasis	4.04e-05	0.000312	CbGpPWpGaD
Pranlukast—NFKB1—Integrated Breast Cancer Pathway—VEGFA—psoriasis	4.03e-05	0.000312	CbGpPWpGaD
Pranlukast—NFKB1—Adaptive Immune System—HLA-E—psoriasis	3.98e-05	0.000308	CbGpPWpGaD
Pranlukast—NFKB1—DNA Damage Response (only ATM dependent)—TP53—psoriasis	3.95e-05	0.000306	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—TAGAP—psoriasis	3.95e-05	0.000306	CbGpPWpGaD
Pranlukast—NFKB1—SIDS Susceptibility Pathways—VEGFA—psoriasis	3.93e-05	0.000304	CbGpPWpGaD
Pranlukast—IL5—Immune System—HLA-A—psoriasis	3.92e-05	0.000303	CbGpPWpGaD
Pranlukast—NFKB1—MyD88-independent cascade—IL6—psoriasis	3.91e-05	0.000302	CbGpPWpGaD
Pranlukast—NFKB1—Cellular Senescence—JUN—psoriasis	3.9e-05	0.000302	CbGpPWpGaD
Pranlukast—TNF—Alzheimers Disease—TP53—psoriasis	3.89e-05	0.000301	CbGpPWpGaD
Pranlukast—ABCC2—Transmembrane transport of small molecules—CP—psoriasis	3.83e-05	0.000296	CbGpPWpGaD
Pranlukast—NFKB1—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	3.82e-05	0.000296	CbGpPWpGaD
Pranlukast—NFKB1—Toll-like Receptor Signaling Pathway—IL6—psoriasis	3.81e-05	0.000295	CbGpPWpGaD
Pranlukast—IL5—Hemostasis—VEGFA—psoriasis	3.77e-05	0.000292	CbGpPWpGaD
Pranlukast—TNF—Regulation of toll-like receptor signaling pathway—JUN—psoriasis	3.75e-05	0.00029	CbGpPWpGaD
Pranlukast—IL5—Immune System—CRP—psoriasis	3.74e-05	0.000289	CbGpPWpGaD
Pranlukast—NFKB1—Senescence-Associated Secretory Phenotype (SASP)—IL6—psoriasis	3.73e-05	0.000288	CbGpPWpGaD
Pranlukast—CYSLTR1—GPCR ligand binding—CXCL8—psoriasis	3.72e-05	0.000288	CbGpPWpGaD
Pranlukast—CYSLTR1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	3.71e-05	0.000287	CbGpPWpGaD
Pranlukast—TNF—Apoptosis—TP53—psoriasis	3.71e-05	0.000287	CbGpPWpGaD
Pranlukast—NFKB1—Regulation of toll-like receptor signaling pathway—TNF—psoriasis	3.69e-05	0.000285	CbGpPWpGaD
Pranlukast—TNF—SIDS Susceptibility Pathways—CXCL8—psoriasis	3.68e-05	0.000285	CbGpPWpGaD
Pranlukast—ABCC2—Transmembrane transport of small molecules—CARM1—psoriasis	3.65e-05	0.000282	CbGpPWpGaD
Pranlukast—NFKB1—Signaling by Interleukins—IL6—psoriasis	3.64e-05	0.000282	CbGpPWpGaD
Pranlukast—TNF—Regulation of toll-like receptor signaling pathway—NFKB1—psoriasis	3.61e-05	0.00028	CbGpPWpGaD
Pranlukast—IL5—Immune System—HLA-DRB1—psoriasis	3.58e-05	0.000277	CbGpPWpGaD
Pranlukast—NFKB1—Activated TLR4 signalling—IL6—psoriasis	3.51e-05	0.000272	CbGpPWpGaD
Pranlukast—NFKB1—Cytokine Signaling in Immune system—TYK2—psoriasis	3.48e-05	0.000269	CbGpPWpGaD
Pranlukast—NFKB1—Innate Immune System—SOCS1—psoriasis	3.46e-05	0.000268	CbGpPWpGaD
Pranlukast—IL5—Immune System—ICAM1—psoriasis	3.44e-05	0.000266	CbGpPWpGaD
Pranlukast—TNF—Adipogenesis—STAT3—psoriasis	3.43e-05	0.000265	CbGpPWpGaD
Pranlukast—TNF—SIDS Susceptibility Pathways—JUN—psoriasis	3.42e-05	0.000265	CbGpPWpGaD
Pranlukast—NFKB1—Signaling by NGF—TYK2—psoriasis	3.42e-05	0.000264	CbGpPWpGaD
Pranlukast—IL5—Immune System—NFKBIA—psoriasis	3.41e-05	0.000264	CbGpPWpGaD
Pranlukast—NFKB1—Immune System—ITGAL—psoriasis	3.38e-05	0.000261	CbGpPWpGaD
Pranlukast—NFKB1—Cellular Senescence—STAT3—psoriasis	3.38e-05	0.000261	CbGpPWpGaD
Pranlukast—NFKB1—SIDS Susceptibility Pathways—TNF—psoriasis	3.36e-05	0.00026	CbGpPWpGaD
Pranlukast—NFKB1—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	3.34e-05	0.000258	CbGpPWpGaD
Pranlukast—NFKB1—Adaptive Immune System—SOCS1—psoriasis	3.32e-05	0.000257	CbGpPWpGaD
Pranlukast—NFKB1—Toll Like Receptor 4 (TLR4) Cascade—IL6—psoriasis	3.3e-05	0.000256	CbGpPWpGaD
Pranlukast—TNF—SIDS Susceptibility Pathways—NFKB1—psoriasis	3.3e-05	0.000255	CbGpPWpGaD
Pranlukast—TNF—Selenium Micronutrient Network—IL6—psoriasis	3.27e-05	0.000253	CbGpPWpGaD
Pranlukast—NFKB1—Cytokine Signaling in Immune system—IFNG—psoriasis	3.26e-05	0.000252	CbGpPWpGaD
Pranlukast—TNF—MAPK Signaling Pathway—JUN—psoriasis	3.23e-05	0.00025	CbGpPWpGaD
Pranlukast—IL5—Signaling Pathways—SOCS1—psoriasis	3.21e-05	0.000248	CbGpPWpGaD
Pranlukast—NFKB1—Cellular responses to stress—CXCL8—psoriasis	3.17e-05	0.000245	CbGpPWpGaD
Pranlukast—NFKB1—MAPK Signaling Pathway—TNF—psoriasis	3.17e-05	0.000245	CbGpPWpGaD
Pranlukast—NFKB1—Immune System—REL—psoriasis	3.16e-05	0.000244	CbGpPWpGaD
Pranlukast—TNF—TNF alpha Signaling Pathway—IL6—psoriasis	3.16e-05	0.000244	CbGpPWpGaD
Pranlukast—TNF—MAPK Signaling Pathway—NFKB1—psoriasis	3.11e-05	0.00024	CbGpPWpGaD
Pranlukast—NFKB1—Immune System—IFIH1—psoriasis	3.07e-05	0.000237	CbGpPWpGaD
Pranlukast—IL5—Signaling by GPCR—TYK2—psoriasis	3.06e-05	0.000237	CbGpPWpGaD
Pranlukast—NFKB1—Integrated Breast Cancer Pathway—TP53—psoriasis	3.04e-05	0.000236	CbGpPWpGaD
Pranlukast—TNF—SIDS Susceptibility Pathways—VEGFA—psoriasis	2.99e-05	0.000231	CbGpPWpGaD
Pranlukast—NFKB1—Regulation of toll-like receptor signaling pathway—IL6—psoriasis	2.98e-05	0.00023	CbGpPWpGaD
Pranlukast—NFKB1—Innate Immune System—HLA-B—psoriasis	2.95e-05	0.000228	CbGpPWpGaD
Pranlukast—NFKB1—Cellular responses to stress—JUN—psoriasis	2.95e-05	0.000228	CbGpPWpGaD
Pranlukast—NFKB1—Adaptive Immune System—CD8A—psoriasis	2.95e-05	0.000228	CbGpPWpGaD
Pranlukast—NFKB1—Toll-Like Receptors Cascades—IL6—psoriasis	2.94e-05	0.000228	CbGpPWpGaD
Pranlukast—IL5—GPCR downstream signaling—CXCL8—psoriasis	2.93e-05	0.000227	CbGpPWpGaD
Pranlukast—TNF—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	2.91e-05	0.000225	CbGpPWpGaD
Pranlukast—NFKB1—Immune System—HLA-C—psoriasis	2.91e-05	0.000225	CbGpPWpGaD
Pranlukast—TNF—Toll-like Receptor Signaling Pathway—IL6—psoriasis	2.91e-05	0.000225	CbGpPWpGaD
Pranlukast—NFKB1—Developmental Biology—LEP—psoriasis	2.89e-05	0.000224	CbGpPWpGaD
Pranlukast—NFKB1—Immune System—TNFAIP3—psoriasis	2.87e-05	0.000222	CbGpPWpGaD
Pranlukast—NFKB1—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	2.86e-05	0.000221	CbGpPWpGaD
Pranlukast—IL5—Hemostasis—TP53—psoriasis	2.85e-05	0.00022	CbGpPWpGaD
Pranlukast—NFKB1—Adaptive Immune System—HLA-B—psoriasis	2.84e-05	0.000219	CbGpPWpGaD
Pranlukast—TNF—Spinal Cord Injury—TP53—psoriasis	2.83e-05	0.000219	CbGpPWpGaD
Pranlukast—TNF—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	2.8e-05	0.000217	CbGpPWpGaD
Pranlukast—NFKB1—MAPK Signaling Pathway—TP53—psoriasis	2.8e-05	0.000216	CbGpPWpGaD
Pranlukast—IL5—Immune System—TYK2—psoriasis	2.79e-05	0.000216	CbGpPWpGaD
Pranlukast—NFKB1—Myometrial Relaxation and Contraction Pathways—IL6—psoriasis	2.73e-05	0.000211	CbGpPWpGaD
Pranlukast—NFKB1—SIDS Susceptibility Pathways—IL6—psoriasis	2.71e-05	0.00021	CbGpPWpGaD
Pranlukast—IL5—Signaling by GPCR—CXCL8—psoriasis	2.66e-05	0.000206	CbGpPWpGaD
Pranlukast—NFKB1—Adaptive Immune System—HLA-A—psoriasis	2.63e-05	0.000203	CbGpPWpGaD
Pranlukast—IL5—Immune System—IFNG—psoriasis	2.62e-05	0.000202	CbGpPWpGaD
Pranlukast—NFKB1—Innate Immune System—CRP—psoriasis	2.61e-05	0.000202	CbGpPWpGaD
Pranlukast—TNF—Spinal Cord Injury—IL6—psoriasis	2.59e-05	0.0002	CbGpPWpGaD
Pranlukast—NFKB1—Cellular responses to stress—VEGFA—psoriasis	2.58e-05	0.000199	CbGpPWpGaD
Pranlukast—NFKB1—Cellular Senescence—TP53—psoriasis	2.58e-05	0.000199	CbGpPWpGaD
Pranlukast—NFKB1—Cellular responses to stress—STAT3—psoriasis	2.55e-05	0.000197	CbGpPWpGaD
Pranlukast—TNF—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	2.54e-05	0.000197	CbGpPWpGaD
Pranlukast—IL5—Immune System—CD4—psoriasis	2.53e-05	0.000196	CbGpPWpGaD
Pranlukast—NFKB1—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	2.52e-05	0.000195	CbGpPWpGaD
Pranlukast—NFKB1—Developmental Biology—PPARG—psoriasis	2.52e-05	0.000195	CbGpPWpGaD
Pranlukast—NFKB1—Fc epsilon receptor (FCERI) signaling—IL6—psoriasis	2.45e-05	0.00019	CbGpPWpGaD
Pranlukast—NFKB1—Cytokine Signaling in Immune system—STAT3—psoriasis	2.43e-05	0.000188	CbGpPWpGaD
Pranlukast—NFKB1—Immune System—HLA-E—psoriasis	2.41e-05	0.000187	CbGpPWpGaD
Pranlukast—NFKB1—Adaptive Immune System—HLA-DRB1—psoriasis	2.4e-05	0.000186	CbGpPWpGaD
Pranlukast—NFKB1—Signaling by NGF—STAT3—psoriasis	2.39e-05	0.000185	CbGpPWpGaD
Pranlukast—TNF—Adipogenesis—IL6—psoriasis	2.39e-05	0.000185	CbGpPWpGaD
Pranlukast—NFKB1—Innate Immune System—NFKBIA—psoriasis	2.38e-05	0.000184	CbGpPWpGaD
Pranlukast—IL5—Signaling Pathways—APOE—psoriasis	2.37e-05	0.000183	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—CCL20—psoriasis	2.37e-05	0.000183	CbGpPWpGaD
Pranlukast—IL5—Signaling Pathways—LEP—psoriasis	2.37e-05	0.000183	CbGpPWpGaD
Pranlukast—NFKB1—Cellular Senescence—IL6—psoriasis	2.36e-05	0.000182	CbGpPWpGaD
Pranlukast—NFKB1—Adaptive Immune System—ICAM1—psoriasis	2.3e-05	0.000178	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—SOCS1—psoriasis	2.3e-05	0.000178	CbGpPWpGaD
Pranlukast—NFKB1—Adaptive Immune System—NFKBIA—psoriasis	2.29e-05	0.000177	CbGpPWpGaD
Pranlukast—TNF—Apoptosis—TP53—psoriasis	2.27e-05	0.000176	CbGpPWpGaD
Pranlukast—TNF—Regulation of toll-like receptor signaling pathway—IL6—psoriasis	2.27e-05	0.000176	CbGpPWpGaD
Pranlukast—IL5—Immune System—JUN—psoriasis	2.26e-05	0.000175	CbGpPWpGaD
Pranlukast—NFKB1—Developmental Biology—TYK2—psoriasis	2.21e-05	0.000171	CbGpPWpGaD
Pranlukast—IL5—Signaling Pathways—NFKBIA—psoriasis	2.21e-05	0.000171	CbGpPWpGaD
Pranlukast—TNF—Developmental Biology—LEP—psoriasis	2.2e-05	0.00017	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling by GPCR—TYK2—psoriasis	2.19e-05	0.00017	CbGpPWpGaD
Pranlukast—IL5—Immune System—NFKB1—psoriasis	2.18e-05	0.000168	CbGpPWpGaD
Pranlukast—TNF—MAPK Signaling Pathway—TP53—psoriasis	2.13e-05	0.000165	CbGpPWpGaD
Pranlukast—CYSLTR1—GPCR downstream signaling—CXCL8—psoriasis	2.1e-05	0.000163	CbGpPWpGaD
Pranlukast—TNF—SIDS Susceptibility Pathways—IL6—psoriasis	2.07e-05	0.00016	CbGpPWpGaD
Pranlukast—NFKB1—Immune System—SOCS1—psoriasis	2.02e-05	0.000156	CbGpPWpGaD
Pranlukast—IL5—Immune System—STAT3—psoriasis	1.96e-05	0.000151	CbGpPWpGaD
Pranlukast—NFKB1—Innate Immune System—TYK2—psoriasis	1.95e-05	0.000151	CbGpPWpGaD
Pranlukast—NFKB1—Cellular responses to stress—TP53—psoriasis	1.95e-05	0.000151	CbGpPWpGaD
Pranlukast—TNF—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	1.92e-05	0.000149	CbGpPWpGaD
Pranlukast—TNF—Developmental Biology—PPARG—psoriasis	1.92e-05	0.000148	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling by GPCR—CXCL8—psoriasis	1.91e-05	0.000148	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—NDUFA5—psoriasis	1.81e-05	0.00014	CbGpPWpGaD
Pranlukast—IL5—Signaling Pathways—TYK2—psoriasis	1.81e-05	0.00014	CbGpPWpGaD
Pranlukast—NFKB1—Immune System—CD8A—psoriasis	1.79e-05	0.000138	CbGpPWpGaD
Pranlukast—NFKB1—Cellular responses to stress—IL6—psoriasis	1.78e-05	0.000138	CbGpPWpGaD
Pranlukast—NFKB1—Innate Immune System—CD4—psoriasis	1.76e-05	0.000136	CbGpPWpGaD
Pranlukast—NFKB1—Immune System—HLA-B—psoriasis	1.72e-05	0.000133	CbGpPWpGaD
Pranlukast—NFKB1—Cytokine Signaling in Immune system—IL6—psoriasis	1.7e-05	0.000132	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—LEP—psoriasis	1.7e-05	0.000131	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—APOE—psoriasis	1.7e-05	0.000131	CbGpPWpGaD
Pranlukast—NFKB1—Adaptive Immune System—CD4—psoriasis	1.69e-05	0.000131	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.69e-05	0.00013	CbGpPWpGaD
Pranlukast—TNF—Developmental Biology—TYK2—psoriasis	1.68e-05	0.00013	CbGpPWpGaD
Pranlukast—NFKB1—Signaling by NGF—IL6—psoriasis	1.67e-05	0.000129	CbGpPWpGaD
Pranlukast—NFKB1—Immune System—HLA-A—psoriasis	1.59e-05	0.000123	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—NFKBIA—psoriasis	1.58e-05	0.000122	CbGpPWpGaD
Pranlukast—NFKB1—Innate Immune System—JUN—psoriasis	1.58e-05	0.000122	CbGpPWpGaD
Pranlukast—IL5—Signaling Pathways—CXCL8—psoriasis	1.57e-05	0.000122	CbGpPWpGaD
Pranlukast—NFKB1—Developmental Biology—VEGFA—psoriasis	1.56e-05	0.000121	CbGpPWpGaD
Pranlukast—NFKB1—Developmental Biology—STAT3—psoriasis	1.55e-05	0.00012	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—CYP2S1—psoriasis	1.54e-05	0.000119	CbGpPWpGaD
Pranlukast—NFKB1—Immune System—CRP—psoriasis	1.52e-05	0.000118	CbGpPWpGaD
Pranlukast—IL5—Signaling by GPCR—IL6—psoriasis	1.5e-05	0.000116	CbGpPWpGaD
Pranlukast—IL5—Signaling Pathways—JUN—psoriasis	1.46e-05	0.000113	CbGpPWpGaD
Pranlukast—NFKB1—Immune System—HLA-DRB1—psoriasis	1.46e-05	0.000113	CbGpPWpGaD
Pranlukast—IL5—Signaling Pathways—NFKB1—psoriasis	1.41e-05	0.000109	CbGpPWpGaD
Pranlukast—NFKB1—Immune System—ICAM1—psoriasis	1.4e-05	0.000108	CbGpPWpGaD
Pranlukast—NFKB1—Immune System—NFKBIA—psoriasis	1.39e-05	0.000107	CbGpPWpGaD
Pranlukast—IL5—Immune System—IL6—psoriasis	1.37e-05	0.000106	CbGpPWpGaD
Pranlukast—NFKB1—Developmental Biology—TNF—psoriasis	1.34e-05	0.000104	CbGpPWpGaD
Pranlukast—TNF—Developmental Biology—NFKB1—psoriasis	1.31e-05	0.000101	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—SOCS1—psoriasis	1.3e-05	0.000101	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—TYK2—psoriasis	1.3e-05	0.0001	CbGpPWpGaD
Pranlukast—IL5—Signaling Pathways—VEGFA—psoriasis	1.28e-05	9.88e-05	CbGpPWpGaD
Pranlukast—IL5—Signaling Pathways—STAT3—psoriasis	1.26e-05	9.79e-05	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—NDUFA5—psoriasis	1.19e-05	9.23e-05	CbGpPWpGaD
Pranlukast—TNF—Developmental Biology—VEGFA—psoriasis	1.19e-05	9.2e-05	CbGpPWpGaD
Pranlukast—TNF—Developmental Biology—STAT3—psoriasis	1.18e-05	9.11e-05	CbGpPWpGaD
Pranlukast—NFKB1—Immune System—TYK2—psoriasis	1.14e-05	8.78e-05	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—CXCL8—psoriasis	1.13e-05	8.73e-05	CbGpPWpGaD
Pranlukast—NFKB1—Developmental Biology—IL6—psoriasis	1.08e-05	8.35e-05	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling by GPCR—IL6—psoriasis	1.07e-05	8.31e-05	CbGpPWpGaD
Pranlukast—NFKB1—Immune System—IFNG—psoriasis	1.06e-05	8.23e-05	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—JUN—psoriasis	1.05e-05	8.12e-05	CbGpPWpGaD
Pranlukast—NFKB1—Immune System—CD4—psoriasis	1.03e-05	7.94e-05	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—CYP2S1—psoriasis	1.01e-05	7.85e-05	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—NFKB1—psoriasis	1.01e-05	7.82e-05	CbGpPWpGaD
Pranlukast—IL5—Signaling Pathways—TP53—psoriasis	9.65e-06	7.47e-05	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—APOE—psoriasis	9.62e-06	7.44e-05	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—LEP—psoriasis	9.62e-06	7.44e-05	CbGpPWpGaD
Pranlukast—NFKB1—Innate Immune System—IL6—psoriasis	9.53e-06	7.38e-05	CbGpPWpGaD
Pranlukast—NFKB1—Immune System—JUN—psoriasis	9.19e-06	7.11e-05	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—VEGFA—psoriasis	9.17e-06	7.09e-05	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—STAT3—psoriasis	9.08e-06	7.02e-05	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—NFKBIA—psoriasis	8.96e-06	6.93e-05	CbGpPWpGaD
Pranlukast—IL5—Signaling Pathways—IL6—psoriasis	8.84e-06	6.84e-05	CbGpPWpGaD
Pranlukast—TNF—Developmental Biology—IL6—psoriasis	8.23e-06	6.36e-05	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism of lipids and lipoproteins—APOE—psoriasis	8.06e-06	6.24e-05	CbGpPWpGaD
Pranlukast—NFKB1—Immune System—STAT3—psoriasis	7.95e-06	6.15e-05	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—CARM1—psoriasis	7.51e-06	5.81e-05	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—TYK2—psoriasis	7.34e-06	5.68e-05	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	7.02e-06	5.43e-05	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—TP53—psoriasis	6.93e-06	5.36e-05	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—CXCL8—psoriasis	6.39e-06	4.95e-05	CbGpPWpGaD
Pranlukast—CYSLTR1—Signaling Pathways—IL6—psoriasis	6.34e-06	4.91e-05	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—JUN—psoriasis	5.94e-06	4.6e-05	CbGpPWpGaD
Pranlukast—NFKB1—Immune System—IL6—psoriasis	5.55e-06	4.3e-05	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—VEGFA—psoriasis	5.19e-06	4.02e-05	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—STAT3—psoriasis	5.14e-06	3.98e-05	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—CARM1—psoriasis	4.95e-06	3.83e-05	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—CAT—psoriasis	4.62e-06	3.57e-05	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—TP53—psoriasis	3.92e-06	3.03e-05	CbGpPWpGaD
Pranlukast—NFKB1—Signaling Pathways—IL6—psoriasis	3.59e-06	2.78e-05	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—APOE—psoriasis	3.59e-06	2.78e-05	CbGpPWpGaD
Pranlukast—CYP2C9—Metabolism—PPARG—psoriasis	3.13e-06	2.42e-05	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—CAT—psoriasis	3.05e-06	2.36e-05	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—APOE—psoriasis	2.37e-06	1.83e-05	CbGpPWpGaD
Pranlukast—CYP3A4—Metabolism—PPARG—psoriasis	2.06e-06	1.6e-05	CbGpPWpGaD
